• 主管部门:
  • 中国科学院
  • 主办单位:
  • 中科院科技战略咨询研究院
  • 出版单位:
  • 世界科学技术杂志社
    科学出版社
  • 主编:
  • 陈凯先
  • 执行主编:
  • 胡镜清 陈士林 叶阳
  • 副主编:
  • (按姓氏笔划排列)王 伟 王 阶 王拥军 王喜军 孔令义 吕文亮 孙晓波 李 萍 李志刚 张卫东 陈立典 果德安 罗国安 赵军宁 徐宏喜 高秀梅 唐旭东 梁繁荣 葛金文
  • 名誉社长:
  • 徐伟宣
  • 社长:
  • 张志华
  • 编辑部主任:
  • 王 瑀
  • 编辑部:
  • 张娜娜 马雅静 方垚 王涵 何岸波 郭嫦娥
  • 责任译审:
  • 王晶
  • 国际刊号:
  • 1674-3849
  • 国内刊号:
  • 11-5699/R
  • 社址:
  • 北京市海淀区北四环西路4号中关村人才苑青年人才公寓4单元412房间
  • 邮编:
  • 100190
  • 电话:
  • 010-62616352
  • 网址:
  • www.wst.ac.cn
  • E-mail:
  • wst@casipm.ac.cn
  • 海外发行号:
  • M1644
  • 邮刊代号:
  • 2-534

乌梢蛇祛风片治疗早期类风湿关节炎的临床观察
Clinical Observation on the Treatment of Early Rheumatoid Arthritis with Zaocys Dhumnades Preparations
  
DOI:10.11842/wst.2019.07.033
中文关键词:  乌梢蛇制剂  乌梢蛇祛风片  类风湿关节炎
英文关键词:Zaocys dhumnades preparations, Zaocys dhumnades pill, rheumatoid arthritis
基金项目:上海市卫生和计划生育委员会中医药发展基金(2012QL043A):基于动态规划的乌梢祛风片治疗类风湿关节炎的临床方案优化研究,主持人:沈杰。
作者单位
岳跃兵 浙江中医药大学附属第二医院 杭州 310000 
沈杰 上海市光华中西医结合医院 上海 200000 
唐小蓉 上海市光华中西医结合医院 上海 200000 
郭梦如 上海市光华中西医结合医院 上海 200000 
程鹏 上海市光华中西医结合医院 上海 200000 
沈逸 上海市光华中西医结合医院 上海 200000 
张湛明 上海市光华中西医结合医院 上海 200000 
汪荣盛 上海市光华中西医结合医院 上海 200000 
冯辉 上海市光华中西医结合医院 上海 200000 
何东仪 上海市光华中西医结合医院 上海 200000 
摘要点击次数: 83
全文下载次数: 215
中文摘要:
      目的 探索乌梢蛇祛风片治疗早期类风湿关节炎(Rheumatoid arthritis,RA)的疗效和安全性。方法 以本院早期RA患者(病程小于等于2年)为研究对象,采用开放、随机的研究方法,治疗组服用乌梢蛇祛风片+甲氨蝶呤10 mg qw;对照组单用甲氨蝶呤10 mg qw;疗程为24周,以美国风湿病协会(ACR)规定的RA疾病缓解度(缓解20%、50%、70%即为ACR20、ACR50、ACR70)和中医证候疗效作为评估标准。结果 治疗组完成76例,对照组完成74例。治疗组和对照组达到ACR20有效率分别为71%和52%,两组有统计学差异(P <0.05);两组达到ACR50与ACR70无统计学差异(P > 0.05)。治疗24周后中医证候疗效,治疗组和对照组有效率分别80%和60%,有统计学差异(P < 0.01)。不同病程的RA(病程小于等于6个月和病程大于6个月)患者ACR20/50/70的有效率和中医证候疗效比较均无统计学差异(P > 0.05)。两组患者在试验过程中均未出现严重的不良反应。结论 乌梢蛇祛风片联合甲氨蝶呤治疗早期RA患者的ACR20疗效和中医证候疗效优于单用甲氨蝶呤,安全性良好。
英文摘要:
      Objective To explore the curative effects and safety of Zaocys dhumnades preparations in the treatment of early rheumatoid arthritis. Methods The patients with early rheumatoid arthritis (course less than or equal to 2 years) were treated with open and randomized research methods to observe the efficacy and safety of Zaocys dhumnades preparations. The observation group was treated with the Zaocys dhumnades pill + methotrexate 10 mg qw and the control group was treated by methotrexate 10 mg qw only. The course of treatment was 24 weeks. The degree of remission of RA disease (20%, 50%, 70% of remission is ACR20, ACR50, ACR70) and the curative effect of TCM syndromes are used as evaluation criteria. Results 76 cases were completed in the treatment group and 74 cases in the control group. The effective rate of ACR20 in the treatment group and control group was 71% and 52% , respectively, with statistical difference (P < 0.05). There was no statistically significant difference between ACR50 and ACR70 in the two groups (P > 0.05). After 24 weeks of treatment, the effective rate of the treatment group and control group was 80% and 60% respectively, with statistically significant differences (P < 0.01). There were no statistically significant differences in acr20/50/70 and TCM syndrome efficacy between RA patients with different disease courses (disease course less than or equal to 6 months and disease course more than 6 months) (P > 0.05). There were no serious adverse reactions in both groups. Conclusion the ACR20 efficacy and TCM syndrome efficacy of wuzhaopu qufeng tablet combined with methotrexate in the treatment of early RA patients were better than that of methotrexate alone, and was safe.
查看全文  查看/发表评论  下载PDF阅读器
关闭